<DOC>
	<DOCNO>NCT00503880</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , clofarabine cytarabine , work different way stop growth cancer cell , either kill cell stop divide . Colony-stimulating factor , G-CSF , may increase number immune cell find bone marrow peripheral blood may help immune system recover side effect chemotherapy . Giving clofarabine cytarabine together G-CSF may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose clofarabine see well work give together cytarabine G-CSF treating patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Clofarabine , Cytarabine , G-CSF Treating Patients With Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose ( MTD ) clofarabine administer low-dose cytarabine filgrastim ( G-CSF ) patient intermediate-2 high-risk myelodysplastic syndrome ( MDS ) . - To evaluate efficacy measure hematologic response rate patient treat novel combination drug candidate intensive treatment intermediate-2 high-risk MDS . Secondary - To assess effect quality life patient population . - To assess time acute myeloid leukemia transformation death . - To assess cytogenetic response rate . - To assess change flow cytometric pattern . OUTLINE : This phase I , nonrandomized , dose-escalation study clofarabine follow phase II study . - Phase I : Patients receive clofarabine IV 1 hour low-dose cytarabine subcutaneously ( SC ) day 1-5 . Patients also receive filgrastim ( G-CSF ) SC begin 1 day prior start chemotherapy continue completion chemotherapy blood count recover . Treatment repeat every 6 week 10 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos clofarabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive clofarabine MTD , cytarabine , G-CSF phase I . Quality life assess baseline , prior course 4 , completion study therapy . Patients undergo bone marrow biopsy baseline prior course 3 , 6 , 8 evaluation treatment response . Bone marrow sample analyze myeloblast phenotypic expression profile , include follow parameter : percentage CD34-positive myeloblast ; antigen expression density CD13 , CD34 , CD45 , CD117 ; aberrant myeloblast expression CD4 , CD11c , CD15 , CD56 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed pathologic diagnosis myelodysplastic syndrome International Prognostic Scoring System score intermediate2 highrisk Failed progress 1 prior FDAapproved treatment MDS OR refuse FDAapproved treatment Not candidate intensive standard chemotherapy stem cell transplantation , determine treat physician PATIENT CHARACTERISTICS : ECOG performance status 02 Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 3 time ULN Creatinine &lt; 2.0 mg/dL Not pregnant nursing Fertile patient must use effective contraception No comorbidity condition , opinion investigator , may interfere assessment procedure protocol would decrease life expectancy &lt; 3 month No active , serious infection control oral IV antibiotic PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>